Real-world effectiveness of sofosbuvir plus ribavirin in Japanese patients with genotype 2 HCV infection: A kanagawa prospective, multicenter study

Abstract

The aim of this study was to reveal the real-life effectiveness of sofosbuvir (SOF) with ribavirin (RBV) in Japanese patients with genotype 2 hepatitis C virus infection. A total of 153 patients were enrolled. The rates of SVR at 12 weeks after end of treatment were 94.1%. Of all 9 patients with treatment-failure were relapsers, and no breakthrough cases were observed. The starting RBV doses were reduced in 44 patients. However, RBV dose reduction has no impact on treatment outcome. Male and low-platelet counts were significantly higher in relapsed group than SVR12 group. Factors, which affect the outcome should be farther investigated. SOF plus RBV was found to be well-tolerated with high SVR rate in Japanese "real-life" cohort.